Ozempic® approved in the US for CV risk reduction in people with type 2 diabetes and established CVD

Rybelsus® label updated with additional information from the PIONEER 6 CV outcomes trial


Bagsværd, Denmark, 16 January 2020 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion based on a supplemental New Drug Application (sNDA) for Ozempic®......
. .
Veröffentlicht von: Finanzen.at - Nachrichten Ticker - Thursday, 16 January
Share |